Current research status Retatrutide is currently in Phase 3 clinical trials, with Eli Lilly conducting multiple large-scale studies
Has been shown to decrease pain in damaged areas
Molecular Basis of Local Action The local effect of AOD 9604 injection is closely related to its molecular properties: Receptor specificity AOD 9604 has a high affinity for 3-AR and reduces systemic side effects
Reconstituted AOD-9604 should be kept at 28C, protected from light, and used within 30 days
It supports healing of joint tissue, reduces inflammation, and can improve mobility
Maintain optimal health by supporting strong bones, boosting your immune system, regulating cell growth, enhancing neuromuscular function, and reducing inflammation